DRDATSONS

Members of the Exchange are hereby notified that in terms of Securities and Exchange Board of India (Delisting of Equity Shares) Regulations, 2009, Section 21A of the Securities Contract (Regulations) Act, 1956, Securities Contract (Regulations) Rules, 1957 and Bye Laws & Regulations of National Stock Exchange of India Limited, it has been decided to delist (withdraw the admission to dealings in) equity shares of the Dr. Datson's Labs Limited w.e.f. July 02, 2018.

Members of the Exchange are hereby informed that the Exchange on February 02, 2018 has issued public notice in the newspaper for proposed compulsory delisting of equity shares of the company, in term of Regulation 22 (3) of SEBI (Delisting of Equity shares) Regulation, 2009. A copy of the same shall be available on the NSE website (http://www.nseindia.com) under: Corporates > Latest Announcements and on the Extranet Server (/common/CorporateAnnouncements).

Members of the Exchange are hereby informed that trading in the equity shares of Dr. Datson's Labs Limited will be suspended w.e.f. May 22, 2015 (i.e. closing hours of trading on May 21, 2015) pursuant to order dated 18/02/2015 passed by the Hon ble High Court, Bombay, in Company Petition No. 328 of 2014, the Official Liquidator attached to the said Court has been appointed as the Provisional Liquidator of M/s Dr. Datson's Labs Limited.

Dr. Datson's Labs Limited has informed the Exchange that the Company to submit order copy of Bombay High Court dated February 18, 2015 (uploaded on website on March 27, 2015) and Minutes Copy of Official Liquidator dated April 30, 2015.

Dr. Datson's Labs Limited has informed the Exchange that Mr. Yogesh Patel, has resigned from the post of Company Secretary & Compliance Officer of the Company with effect from May 12, 2015.

Dr. Datson's Labs Limited has informed the Exchange that the creditors of the Company in winding up petitions, vide its order dated February 18, 2015 (uploaded on website on March 27, 2015), appointed the official liquidator attached to the Bombay High Court as the provisional liquidator of Dr. Datsons Labs Limited (the Company ) and directed the provisional liquidator to forthwith take charge/possession of the Company s assets, properties, stock in trade, books of account, bank account and all other assets of the Company.

Finaventure Capital Limited has submitted to the Exchange vide letter dated April 10, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Kannan Vishwanath has submitted to the Exchange vide letter dated April 10, 2015 a copy of disclosure under Regulation 30(1) and 30(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

The Exchange had sought clarification from Dr. Datson's Labs Limited with respect to "Spurt in Price and Volume". The Company has submitted its clarification for the same.

Dr. Datson's Labs Limited has informed the Exchange that Ms. Anjali Jadhav, has been appointed as a Non Executive Additional Director of the Company, with effect from April 2, 2015.

Dr. Datson's Labs Limited has informed the Exchange that Westminster Pharmaceuticals INC Based out of USA has sent us a communication showing interest in Company's contract manufacturing Generic Medicines in Private Label for Westminster Pharmaceuticals INC.

Dr. Datson's Labs Limited has informed the Exchange regarding a press release dated March 12, 2015 on Ochoa Labs to Expand base in Europe through an Exclusive Contract Manufacturing Partnership for Cancer Drugs worth 120 Crore with Dr.Datsons Labs Ltd.

Dr. Datson's Labs Limited has informed the Exchange regarding press release on Dr. Rajendra Kamat ( VC & MD ) of the Company nominated for Receiving The International Aristotle Award in Turket on March 21 and 22, 2015 at Turkey.

Dr. Datson's Labs Limited has informed the Exchange regarding a press release dated March 9, 2015 titled "Dr. Datsons Labs to partner with Clinton Foundation to supply Anti-Malarial Drugs to Eliminate Malaria on UNITAID-CHAI Malaria Treatment Project 2015".

Dr. Datson's Labs Limited vide letter dated March 2, 2015 has submitted the disclosure, under Regulation 13 (3) and (6) of SEBI (Prohibition of Insider Trading) Regulations, 1992, to the Exchange .

Dr. Datson's Labs Limited has informed the Exchange vide letter dated March 2, 2015 regarding a press release titled "India's Dr. Datsons Labs Ink Marketing And Supply Agreement with Yemen's ALMUGDH PHARMA to sell its drugs in YEMEN".

Sparrow Asia Diversified opportunities Fund has submitted to the Exchange vide letter dated February 27, 2015 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has informed the Exchange that the following changes in designation have taken place for the respective person:- 1. Mr. Rajendra Kamath, as a Vice Chairman and Managing Director of the company with effect from February 15, 2015. 2. Mr. Mahesh Vaidya, as Non Executive Chairman of the company with effect from February 15, 2015.

Dr. Datson\'s Labs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 31-Dec-2014.

Dr. Datson's Labs Limited has informed the Exchange that in the Meeting of the Board of Directors of the Company held on February 14, 2015 it was decided: (1) To appoint Mr. Mahesh Vaidya, as the Vice Chairman and Managing Director of the company w.e.f. February 14, 2015. (2) To accept the resignation of Dr. Kannan Vishwanath, as the Vice Chairman and Managing Director of the company w.e.f. February 14, 2015

Dr. Datson's Labs Limited has informed the Exchange regarding appointment of Mr. Sameer Talim, Chief Executive officer of the Company, with effect from February 9, 2015.

Leman Diversified Fund has submitted to the Exchange, vide letter dated February 2, 2015 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has informed the Exchange that as per the Company's Code of Conduct for Prohibition of Insider Trading, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the Company will be closed for the purpose of declaration of financial results of the Company for the quarter ended December 31, 2014 from February 2, 2015 to February 16, 2015. Accordingly, all the Designated Employees (including Directors) of the Company have been intimated not to enter into any trans

SPARROW ASIA DIVERSIFIED OPPORTUNITIES FUND has submitted to the Exchange vide letter dated January 15, 2015 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has informed the Exchange regarding outcome of the Board Meeting of the Company held on January 05, 2015.

Dr. Kannan Vishwanath has submitted to the Exchange vide letter dated January 1, 2015 a copy of disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has informed the Exchange vide letter dated December 22, 2014 regarding "Message from Minister of Health & Family Welfare Government of India."

Dr. Datson's Labs Limited has informed the Exchange regarding a Outcome of Board Meeting of the Company held on December 15, 2014.

Dr. Datson's Labs Limited has submitted to the Exchange, vide letter dated December 2, 2014, a copy of the disclosure pursuant to Regulation 13(1), 13(4), 13(4A) and 13(6) of SEBI (Prohibition of Insider Trading) Regulations, 1992.

Finaventure Capital Limited has submitted to the Exchange vide letter dated December 02, 2014 a copy of Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated November 27, 2014 a copy of disclosure pursuant to Regulation 13(1), 13(4), 13(4A) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Dr. Datson's Labs Limited has informed the Exchange regarding press release dated November 27, 2014, titled "Dr. Datson's Labs to receive "Transformational & Come Back Company of the year" for sustained healthcare Innovations".

Leman Diversified Fund has submitted to the Exchange, vide letter dated November 26, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Stream Value Fund has submitted to the Exchange, vide letter dated November 26, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011.

Dr. Datson's Labs Limited has informed the Exchange that the Company won The Coveted "Swiss International Quality Certificate".

Dr. Datson's Labs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Sep-2014.

Dr. Datson's Labs Limited has informed the Exchange regarding Outcome of Board Meeting held on November 11, 2014.

Dr. Datson's Labs Limited has informed the Exchange that Mr. Giridhar Gopal Pulleti, Director of the Company, has tendered his resignation from the directorship of the company with effect from October 27, 2014.

Dr. Datson's Labs Limited has informed the Exchange that as per the Company's Code of Conduct for Prohibition of Insider Trading, framed pursuant to the Securities and Exchange Board of India (Prohibition of Insider Trading) Regulations, 1992, the trading window for dealing in the securities of the Company will be closed for the purpose of declaration of financial results of the Company for the quarter ended September 30, 2014 from October 31, 2014 to November 15, 2014. Accordingly, all the Designated Employees (including Directors) of the Company have been intimated not to enter into any tran

Dr. Datson's Labs Limited has submitted to the Exchange a copy of the offering circular dated October 21, 2014, offer of US$13,000,000 5.32% Unsecured Foreign Currency Convertible Bonds due 2019 Convertible into Equity Shares.

Dr. Datson's Labs Limited has informed the Exchange that the Company has closed its FCCB Issue on October 21, 2014. The said issue was opened for subscription on October 17, 2014. As decided in the Meeting of the Board of Directors of the Company held on October 21, 2014, the Board of Directors has allotted 130 Bonds of US$100,000 each aggregating US$ 13 million.

Dr. Datson's Labs Limited has informed the Exchange that Board in its meeting held on October 17, 2014 have decided that the date of opening of issuance of FCCB up to USD 13.00 million is on October 17, 2014.

Dr. Datson's Labs Limited has informed the Exchange regarding Outcome of the Annual General Meeting held on September 30, 2014.

Dr. Datson's Labs Limited has informed the Exchange regarding appointment of Mr. Rajendra Kamath, Non Executive Chairman of the Company, with effect from August 21, 2014.

Dr. Datson's Labs Limited has informed the Exchange that the Company has fixed Book Closure from September 24, 2014 to September 30, 2014 (both days inclusive) for the purpose of Annual General Meeting of the Company scheduled to be held on September 30, 2014.

Dr. Datson's Labs Limited has informed the Exchange that the Board of Directors of the Company held on August 14, 2014, decided: 1) Adopted and Approved the Notice & Directors Report along with the Corporate Governance Report of the Company for the financial year 2013-14; 2) Authorize Dr. Kannan Vishwanath, Vice Chairman & Managing Director and/or Mr. Yogesh Patel, Company Secretary of the Company, to oversee the entire E-voting Process at the AGM of the Company; 3) Appointed Mr. Deep Shukla, Practicing Company Secretary as a Scrutinizer to conduct the entire voting Process at the A

Dr. Datson's Labs Limited has submitted to the exchange the standalone financial results along with the Limited Review Report for the period ended 30-Jun-2014.

Dr. Datson's Labs Limited has informed the Exchange regarding the Results of Postal Ballot.

Dr. Datson's Labs Limited has submitted to the Exchange vide letter dated August 12, 2014 a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.

Stream Value Fund has submitted to the Exchange vide letter dated August 07, 2014 a copy of disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 along with a copy of disclosure pursuant to Regulation 13(1) and 13(6) of the SEBI (Prohibition of Insider Trading) Regulations, 1992.